Investments
98Portfolio Exits
18Funds
1Partners & Customers
1About Dolby Family Ventures
Dolby Family Ventures is an early stage venture firm focused on building great technology companies. The firm partners with best-in-class innovators and strong investment syndicate partners at the seed stage of a company's development. The fund honors the legacy of Ray Dolby and his commitment to engineers and their vision to solve the world's toughest problems. Dolby Family Ventures formalizes the Dolby family's ongoing multi-generational commitment to supporting talented entrepreneurs.

Want to inform investors similar to Dolby Family Ventures about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Dolby Family Ventures News
May 9, 2023
Genemod – a cloud-based workspace collaboration software for biopharma R&D teams – announced it raised $4.5 million in seed funding co-led by defy.vc and LDV Partners with participation from Dolby Family Ventures and Vulcan/Cercano Ventures. Over the past year, Genemod has expanded into the biopharma R&D space working with teams from startups to enterprise companies including AstraZeneca, Bristol-Myers, Merck, and more. And working across siloed spreadsheets, updating data in real-time, and collaborating on projects in disparate geographical locations are just several examples of how teams using Genemod are able to eliminate busywork and other barriers so they can focus on developments in biopharma. The legacy R&D software and other traditional methods are decentralized, disorganized, and inefficient, resulting in higher healthcare costs. And Genemod is working to be the solution to this problem by building a dynamic cloud-based research platform designed for research teams to house their entire R&D lifecycle: from data acquisition and project documentation to inventory management and reporting. The intuitive interface enables users to easily visualize their data and track progress and updates – including what changes are made by whom. Genemod is known for working to solve the reproducibility crisis – which is an ongoing phenomenon that continues to throw off research scientists. Reproducibility is essentially the ability to recreate the same experiment to achieve the same results. While this could sound simple in theory, disorganized data and a chronic lack of cloud-based organizational tools (among other issues) mean that experiment results continue to be inconsistent, costing the US government and researchers billions per year. Discovery and clinical translation are no longer driven by siloed one-off experimentation but compounding from accelerating gains in scale of data, reproducibility, and fidelity of experiment. The COVID-19 pandemic played a major role in accelerating Genemod’s innovation and development with Genemod playing an important role in aiding pandemic-related research. And the pandemic overall led to collaboration between an increasing number of companies and research teams in a variety of industries. This includes the pharmaceutical and biotech business, which are leaning into dynamic, market-driven solutions in order to meet ever-increasing global healthcare and environmental challenges. KEY QUOTES: “We believe that scientists must be empowered with tools to discover and develop medicines and ultimately get them to market faster than ever before. That’s why we built Genemod – to transform the way biopharma companies operate.” — Jacob Lee, CEO and Co-founder of Genemod “Genemod aims to be the go-to standard for research scientists just as how designers use Figma and engineers use Jira.” — Jin Choe, Co-founder at Genemod “Biotechnology is one of the fastest growing industries in existence, and the software that powers efficiency and communication in labs has the potential to radically transform the world. Genemod is positioned to solve some of the world’s most pressing problems in the coming decades, from pandemics and other diseases to climate change. We are pleased to be investing in this great team and company and look forward to partnering with them as they continue to scale and grow.” — Neil Sequeira, Founder and Partner at defy.vc Trending on Pulse 2.0
Dolby Family Ventures Investments
98 Investments
Dolby Family Ventures has made 98 investments. Their latest investment was in Paradromics as part of their Series A on May 5, 2023.

Dolby Family Ventures Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
5/18/2023 | Series A | Paradromics | $33M | No | 6 | |
5/4/2023 | Seed VC - II | Genemod | $4.5M | Yes | 8 | |
4/12/2023 | Unattributed VC | Kebotix | $2.21M | Yes | 2 | |
4/5/2023 | Series D | |||||
3/20/2023 | Seed VC - II |
Date | 5/18/2023 | 5/4/2023 | 4/12/2023 | 4/5/2023 | 3/20/2023 |
---|---|---|---|---|---|
Round | Series A | Seed VC - II | Unattributed VC | Series D | Seed VC - II |
Company | Paradromics | Genemod | Kebotix | ||
Amount | $33M | $4.5M | $2.21M | ||
New? | No | Yes | Yes | ||
Co-Investors | |||||
Sources | 6 | 8 | 2 |
Dolby Family Ventures Portfolio Exits
18 Portfolio Exits
Dolby Family Ventures has 18 portfolio exits. Their latest portfolio exit was Tempo Automation on November 23, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
11/23/2022 | Reverse Merger | 4 | |||
12/10/2021 | Acquired | 2 | |||
10/8/2021 | IPO | Public | 4 | ||
Date | 11/23/2022 | 12/10/2021 | 10/8/2021 | ||
---|---|---|---|---|---|
Exit | Reverse Merger | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 4 | 2 | 4 |
Dolby Family Ventures Fund History
1 Fund History
Dolby Family Ventures has 1 fund, including Dolby Family Ventures.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
6/16/2014 | Dolby Family Ventures | 1 |
Closing Date | 6/16/2014 |
---|---|
Fund | Dolby Family Ventures |
Fund Type | |
Status | |
Amount | |
Sources | 1 |
Dolby Family Ventures Partners & Customers
1 Partners and customers
Dolby Family Ventures has 1 strategic partners and customers. Dolby Family Ventures recently partnered with Gladstone Institutes, and Evotec SE on July 7, 2015.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
7/23/2015 | Partner | United States, and Germany | David Dolby , Managing Director , Dolby Family Ventures , joined forces with Gladstone Institute of Neurological Disease because its research has great potential to change the progression of Alzheimer 's disease . | 1 |
Date | 7/23/2015 |
---|---|
Type | Partner |
Business Partner | |
Country | United States, and Germany |
News Snippet | David Dolby , Managing Director , Dolby Family Ventures , joined forces with Gladstone Institute of Neurological Disease because its research has great potential to change the progression of Alzheimer 's disease . |
Sources | 1 |
Dolby Family Ventures Team
3 Team Members
Dolby Family Ventures has 3 team members, including current Senior Managing Director, Pascal N. Levensohn.
Name | Work History | Title | Status |
---|---|---|---|
Pascal N. Levensohn | Senior Managing Director | Current | |
Name | Pascal N. Levensohn | ||
---|---|---|---|
Work History | |||
Title | Senior Managing Director | ||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.